Cardinal Health's Liberty Dewey breaks down the NDC-12 transition timeline and the vendor, association and wholesaler support smaller pharmacies will need to get ready.
Commentary|Videos|June 20, 2025
Peer Exchange: Understanding the Pharma Supply Chain (Episode 1)
Author(s)Nicholas Saraceno, Senior Editor
In the first part of this roundtable discussion, a panel of subject matter experts introduce themselves, while discussing the strategies that are most effective in ensuring resilience across the global supply chain.
Advertisement
Advertisement
In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, introduced a discussion on the pharmaceutical supply chain, highlighting its complexity and importance in delivering medications safely and efficiently from manufacturers to patients. The conversation explored the roles of various stakeholders, the need for supply chain resilience and quality control, and the growing importance of data management in achieving these goals.
Related to this article
DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
Gregg Gorniak explains how AI, RFID and serialized data are helping trading partners move DSCSA compliance from a regulatory checkbox to a source of shared operational value.
As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
In the final installment of his interview with Pharmaceutical Commerce, Cencora's Ameer Ali outlines how supply chain stakeholders should prepare systems, processes and trading partners for the shift to NDC-12.
In the final installment of his interview with Pharmaceutical Commerce, Cencora's Gregg Gorniak looks back at DSCSA's five-year evolution and where serialized data is creating value beyond compliance.
Cardinal Health's Liberty Dewey outlines the four parallel work streams driving the NDC-12 transition, and why the biggest risk sits in trading partner handoffs rather than any single system.
HDA's Kala Shankle says a two-year national licensure runway for distributors could work, but only if states, the FDA and industry move in parallel.
Advertisement
Advertisement